BIND CEO Says Amgen Deal Marks Nanomedicine Turning Point
(Page 3 of 3)
Russia’s state-owned nanotechnology investment fund. But Minick says the Amgen deal represents the first major investment in nanoparticle-based drugs by a large pharma company.
BIND and Amgen plan to pair the Accurin technology with a cancer compound already developed by Amgen that targets a protein kinase, one of a family of enzymes that play a key role in tumor growth. Most of the newer targeted cancer medicines developed in the past two decades are kinase inhibitors, but Minick said it is always a challenge to ensure that these drugs target only diseased cells and not healthy ones. BIND will add two or more layers of nanoparticles to the kinase inhibitor to give the drug a laser-like focus on the cancer cells.
The Amgen collaboration calls for the two companies to work together on preclinical development, and then Amgen will take over future development and commercialization.The two companies started discussing the possibility of a partnership over the summer, and Minick says the companies want to move a compound into the clinic as quickly as possible. “We have very ambitious plans. We see this as a drug with major clinical impact, and both companies want to take it forward as fast as we can.”
Minick says the deal could yield well above $200 million to BIND, once all the royalties and additional milestone payments are factored in. For example, the deal calls for further payments above the $180.5 million if any drug that emerges from the program is approved for more than one type of cancer.
BIND already has a compound of its own in the clinic, BIND-014 for solid tumors, which combines nanoparticles with the chemotherapy drug docetaxel. The results of the Phase 1 trial, presented last April at the American Society of Clinical Oncology annual meeting, showed antitumor activity in six out of 17 patients with advanced cancer, and it showed activity against tumors that don’t normally respond to docetaxel.